ARCHIVES

Genentech Move Nixes Hospital Discounts: Avastin, Herceptin, Rituxan Now Sold Under Tighter Control by Drug Maker

This article is from The Cancer Letter archive.

Vol. 40 No. 37 | October 3, 2014

Download PDF Visit The Full Archive

Related Articles

DCE Board Ok’s New RFA Programs worth $14 Million

June 29, 1990

In Brief: Hawkins Gets Seat Back On Labor & Human Resources, Loses Subcommittee; Foundation Offers Fellowships

February 11, 1983

Federal Funding: IOM Report Praises DOD Breast Cancer Research Program

August 15, 1997

Study Finds Gene Expression Test Predicts Stage I or II Recurrence

August 30, 2013

NCAB Hung Up On removing $ 45 Million Limit For Core Grants

September 17, 1976

Phase III Afatinib Trial Met Primary Endpoint In Stage IIIb or IV Cancer with EGFR Mutation

June 29, 2012